The National Pharmaceutical Pricing Authority (NPPA) has fixed the retail prices of 37 new drug formulations under the Drugs (Prices Control) Order (DPCO), 2013, through an order issued on December 24, 2025. The decision, published in the Gazette of India, aims to regulate the prices of commonly used medicines across therapeutic segments, while ensuring affordability and transparency for consumers.
The price fixation covers a wide range of formulations, including pain management, anti-infectives, cardiovascular drugs, anti-diabetics, respiratory medicines, nutritional supplements, ophthalmic solutions, injectables and syrups. The prices notified by NPPA are exclusive of Goods and Services Tax (GST), which manufacturers may add only if it is actually payable to the government.
Among widely used combinations, the retail price of Aceclofenac and Paracetamol tablets has been fixed at ₹5.46 per tablet, while Albendazole and Ivermectin suspension has been capped at ₹1.39 per ml. Atorvastatin and Ezetimibe tablets, commonly prescribed for cholesterol management, have been priced at ₹36.12 per tablet.
In the cardiovascular segment, Bisoprolol Fumarate and Telmisartan tablets have been priced in the range of ₹10 to ₹12.18 per tablet, depending on strength and manufacturer. For diabetes management, combinations such as Sitagliptin, Gliclazide (SR) and Metformin (SR) have been capped at ₹22.91 per tablet, while Myo-Inositol and Metformin (SR) tablets have been fixed at ₹23.59 per tablet across different marketers.
The order also includes several pediatric and general care formulations. Mefenamic Acid and Paracetamol oral suspensions have been priced below ₹1 per ml, while Paracetamol-based cold and cough combinations in tablet and syrup forms have been capped between ₹0.95 and ₹5.34 per unit. Vitamin D3 oral solutions and nano syrups containing 60,000 IU have been priced at ₹15.60 per ml.
High-value hospital-use medicines have also been included in the notification. Meropenem and Sulbactam injection has been capped at ₹1,500 per vial, while Multiple Electrolytes with 5% Dextrose injection (500 ml pack) has been priced at ₹133.97. In the respiratory care segment, Glycopyrronium, Formoterol Fumarate and Budesonide inhalation suspension has been fixed at ₹49 per ml.
NPPA clarified that the fixed retail prices apply only to the specific manufacturers and marketers mentioned in the notification who have applied for price fixation under DPCO, 2013. Manufacturers are required to issue updated price lists in Form V and ensure compliance by displaying prices prominently at retail outlets.
The authority has also warned that any overcharging beyond the notified prices will attract recovery of the excess amount along with interest, under the provisions of the DPCO, 2013 read with the Essential Commodities Act, 1955. With this move, NPPA continues its regulatory effort to balance consumer affordability with industry compliance in India’s pharmaceutical market.
